|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | BRCA1和BRCA2在前列腺癌中的作用显示文摘前列腺癌中最大的风险因素之一就是家族遗传史。BRCA2生殖细胞系突变是迄今为止已知的导致前列腺癌的最大遗传性风险因子(65岁以上男性的风险比其他高8.6倍)。尽管BRCA2和BRCA1在前列腺癌形成中的作用还不太清楚,但这两个基因的破坏性突变往往会产生严重癌症表现以及不理想的临床结果。随着全世界前列腺癌发生率的上升,我们需要新的预测前列腺癌以及筛查具有潜在致死性前列腺癌病人的方法。我们这里所探讨的BRCA生殖细胞系突变(主要指BRCA2生殖细胞系突变),就是这样的一种预测方法。我们还将探讨这些突变在前列腺癌治疗方面的作用,并且针对具有相似特征的零散病例的治疗方案提出假设。 | Elena Castro Rosalind Eeles | 2012 | Asian Journal of Andrology2012，14，3： | 11 |
| 2 | Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene☆显示文摘 | Victor R Gordeuk Angela Caleffi Elena Corradini Francesca Ferrara Russell A Jones Oswaldo Castro Onyinye Onyekwere Rick Kittles Elisa Pignatti Giuliana Montosi Cinzia Garuti Innocent T Gangaidzo Z.A.R Gomo Victor M Moyo Tracey A Rouault Patrick MacPhail A | 2003 | Blood Cells Molecules and Diseases2003，，3： | 1 |
| 3 | 源自巴西野生动物的毒液、毒素及其衍生物:药物开发的重要来源(英文)显示文摘在药物研发领域,野生动物的毒液正被广泛研究,许多基于毒液组分的研究以生物技术应用和专利申请形式被报道。巴西拥有丰富的生物多样性,公布的科研论文和专利申请数量显示了该资源是多么重要。本文报道了一份研究最透彻的巴西有毒动物物种清单及从2000年到2013年的专利申请情况,包括源自巴西有毒物种的毒液成份、毒素及其衍生物。分析了涉及物种的数据、产品类型与发明者的国籍。55个专利申请涉及8个种属,响尾蛇、南美巨蝮蛇、矛头蝮蛇、斜蛛占其中78%。其余22%的专利来自巴西游走蛛、巴西金幽灵蝎、巴西捕鸟蛛、叶水蛙的毒液研究。大多数的发明(42%)包括抗癌、免疫调节剂或抗菌的药物,13%的发明为抗毒血清和疫苗,11%为降压成分,9%为镇痛及抗炎成分,其它25%为一些技术和试剂盒。巴西发明家占专利申请比重的49%,而其它国家如美国、德国、俄罗斯和法国同样发表了巴西动物毒液、毒素或衍生物的专利。虽然巴西拥有着大多数有毒物种的专利,但这些专利主要属于其学校和研究机构,药物工业在这方面依然薄弱。迄今为止,在世界范围内,已将巴西的有毒物种运用于药物研发,但大多数的物种可否作为研发的重要工具,仍然需要作进一步的勘探。 | Flavia De Marco Almeid Adriano Monteiro de Castro Pimentat Monica Cristina Oliveiral Maria Elena De Lima | 2015 | 生理学报2015，67，3： | 1 |
| 4 | Long-termfluoxetine treatment modulates cannabinoid type 1receptor-mediated inhibition of adenylyl cyclase in the ratprefrontal cortex through 5-Hydroxytryptamine (1A)receptor-dependent mechanisms 显示文摘 | Mato Susana Vidal Rebeca Castro Elena | 2010 | MolecularPharmacology2010，77，3： | 1 |
| 5 | State of the art of frameworks and middleware for facilitating ruobile and ubiquitous learning development 显示文摘 | Sergio Martin Gabriel Diaz Inmaeulada Plaza Elena Ruiz Manuel Castro Juan Peire | | The Jour- nal of Systems and Software0，201，： | 1 |
| 6 | Frequency of Cognitive Impairment Without Dementia in Patients With Stroke: A Two-Year Follow-Up Study显示文摘 | Soledad Serrano Julio Domingo Elena Rodríguez-Garcia Maria-Dolores Castro Teodoro del Ser | 2007 | Stroke2007，，1： | 1 |
| 7 | Frequency of Cognitive Impairment Without Dementia in Patients With Stroke: A Two-Year Follow-Up Study显示文摘 | Soledad Serrano Julio Domingo Elena Rodríguez-Garcia Maria-Dolores Castro Teodoro del Ser | 2007 | Stroke2007，，1： | 1 |
| 8 | Hepatitis C virus/human T lymphotropic virus 1/2 coinfection:Regional burden and virological outcomes in people who inject drugs显示文摘This review analyses current data concerning co-infection with hepatitis C virus(HCV) and human T lymphotropic virus(HTLV)-1/2 in people who inject drugs(PWID), with a particular focus on disease burden and global implications for virological outcome. In addition, the available treatment options for HTLV-1/2 are summarized and the on-going and likely future research challenges are discussed. The data in this review was obtained from 34 articles on HCV/HTLV-1/2 co-infection in PWID retrieved from the Pub Med literature database and published between 1997 and 2015. Despite unavailable estimates of the burden of HCV/HTLV-1/2 co-infection in general, the epidemiologic constellation of HTLV-1/2 shows high incidence in PWID with history of migration, incarceration, and other blood-borne infectious diseases such as HCV or human immunodeficiency virus. The most recent research data strongly suggest that HTLV-1 co-infection can influence HCV viral load, HCV sustained virological response to α-interferon treatment, and HCV-related liver disease progression. In short, outcome of HCV infection is worse in the context of HTLV-1 co-infection, yet more studies are needed to gain accurate estimations of the burden of HCV/HTLV-1/2 co-infections. Moreover, in the current era of new direct-acting antiviral treatments for HCV and proven HTLV-1/2 treatment options, prospective clinical and treatment studies should be carried out, with particular focus on the PWID patient population, with the aim of improving virological outcomes. | Erika Castro Elena Roger | 2016 | World Journal of Virology2016，5，2： | 1 |
| 9 | Occurrence and ecological risk assessment of pharmaceutical products in the Kadicha river in Lebanon显示文摘Contamination of aquatic systems with pharmaceutical products represents a rising concern.The Kadicha river in Northern Lebanon is an illustrative example of a small Mediterranean river affected by rapid urbanization and population growth.This paper reports the first study on occurrence and ecological risk assessments on selected pharmaceuticals and their metabolites within the Kadicha river.For this purpose,surface water samples were collected over two sampling campaigns from twelve sites impacted by urban,rural,and mixed land uses(residential and agricultural zones)within the Kadicha river basin.Among the studied pharmaceuticals,six compounds(carbamazepine,diclofenac,acetaminophen,sulfamethoxazole,ofloxacin,and atenolol)were detected with detection frequencies and concentrations that vary according to the sampling sites.Carbamazepine was the most frequently detected compound and showed the highest concentrations(not detected-290 ng/L).The presence of pharmaceuticals carbamazepine,ofloxacin(not detected-190 ng/L),and atenolol(not detected-93 ng/L)was related to raw wastewater inputs in the water body,while the presence of sulfamethoxazole(not detected-23 ng/L)was associated with its usage in specific sites with livestock activity.Besides,the presence of acetaminophen(not detected-242 ng/L)and diclofenac(not detected-1055 ng/L)can be affected by their degradation properties in river waters.The highest concentrations were observed in the urbanized downstream area,while the lowest concentrations were within the rural upstream area.Thus,the urbanized downstream area presents the highest potential risks for aquatic species.Moreover,ofloxacin may pose high ecotoxicological risks in this watershed.The levels of contamination with pharmaceuticals do not exceed the concentrations reported in the literature.Furthermore,the levels of carbamazepine,diclofenac,and acetaminophen were more similar to sites receiving raw wastewaters,while the concentration levels of sulfamethoxazole,ofloxacin,and atenolol were more similar to sites receiving treated wastewaters.This paper highlights the need to collect and treat wastewater in this watershed to improve the situation for health and the environment.Monitoring programs on pharmaceutical compounds in Lebanese river waters are needed to better understand the pollution situation and make future public policies on water quality in Lebanon. | Fatme Merhabi Elena Gomez Nancy Ariza Castro Helmieh Amine David Rosain Jalal Halwani Helene Fenet | 2021 | Emerging Contaminants2021，7，1： | 0 |
| 10 | Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease显示文摘BACKGROUND Identifying predictors of therapeutic response is the cornerstone of personalized medicine.AIM To identify predictors of long-term mucosal healing(MH) in patients with Crohn's disease(CD) treated with tumor necrosis factor α(TNF-α) inhibitors.METHODS Prospective single center study. Consecutive patients with clinically active CD requiring treatment with a TNF-α inhibitor were included. A baseline segmental CD Endoscopic Index of Severity(CDEIS) ≥ 10 in at least one segment or the presence of ulcerations were required for inclusion. Clinical, biological and endoscopic data were obtained at baseline, weeks 14 and 46. Endoscopic response(ER) was defined as a decrease ≥ 50% from baseline CDEIS and MH as partial CDEIS ≤ 5 in all segments.RESULTS Of 62 patients were included. At baseline, median CD Activity Index and CDEIS were 201 and 6.7, respectively with a significant reduction after one year of treatment(53 and 3.0 respectively, P < 0.001). At week 14, 56% of patients achieved ER and 34% MH. At week 46, the corresponding percentages were 52%and 44%. Baseline disease characteristics or biomarkers did not predict MH. A decrease from baseline CDEIS at week 14 of at least 80% was the best predictor of MH at week 46(59% sensitivity and 91% specificity; area under the curve =0.778).CONCLUSION Clinical and biomarker data are not useful predictors of response to TNF-αinhibitors in CD, whereas ER to induction therapy, defined as 80% reduction in global CDEIS, is a robust predictor of long-term MH. Achievement of this endoscopic endpoint may be considered as a therapeutic target for anti-TNF-αtherapy. | Ignacio Alfaro Maria Carme Masamunt Nuria Planell Alicia López-García Jesús Castro Marta Gallego Rebeca Barastegui Angel Giner Alejandro Vara Azucena Salas Elena Ricart Julián Panés Ingrid Ordás | 2019 | World Journal of Gastroenterology2019，25，14： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员